- Vital signs: pregnancy-related deaths, United States, 2011-2015, and strategies for prevention, 13 states, 2013-2017.MMWR Morb Mortal Wkly Rep. 2019; 68: 423-429
- Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.Lancet. 2016; 388: 1775-1812
- Systolic hypertension, preeclampsia-related mortality, and stroke in California.Obstet Gynecol. 2019; 133: 1151-1159
- Stroke and severe preeclampsia and eclampsia: a paradigm shift focusing on systolic blood pressure.Obstet Gynecol. 2005; 105: 246-254
- Gestational hypertension and preeclampsia: ACOG Practice Bulletin, Number 222.Obstet Gynecol. 2020; 135: e237-e260
- ACOG Practice Bulletin No. 203: chronic hypertension in pregnancy.Obstet Gynecol. 2019; 133: e26-e50
- Identification of factors associated with delayed treatment of obstetric hypertensive emergencies.Am J Obstet Gynecol. 2020; 223: 250.e1-250.e11
- Factors associated with appropriate treatment of acute-onset severe obstetrical hypertension.Am J Obstet Gynecol. 2021; 225: 329.e1-329.e10
- Early standardized treatment of critical blood pressure elevations is associated with a reduction in eclampsia and severe maternal morbidity.Am J Obstet Gynecol. 2017; 216: 415.e1-415.e5
- Reducing time to treatment for severe maternal hypertension through statewide quality improvement.Am J Obstet Gynecol. 2018; : 218
- Impact statements.(Available at:)https://safehealthcareforeverywoman.org/wp-content/uploads/AIM-Impact-Statements-June-2021.pdfDate: 2021Date accessed: September 28, 2021
- Pulse pressure as a predictor of response to treatment for severe hypertension in pregnancy.Am J Obstet Gynecol MFM. 2021; 3: 100455
- Quality measures in high-risk pregnancies: executive summary of a cooperative workshop of the Society for Maternal-Fetal Medicine, National Institute of Child Health and Human Development, and the American College of Obstetricians and Gynecologists.Am J Obstet Gynecol. 2017; 217: B2-B25
- Risks of parenteral antihypertensive therapy for the treatment of severe maternal hypertension are low.Hypertens Pregnancy. 2016; 35: 123-128
- Society for Maternal-Fetal Medicine (SMFM) Special Report: current approaches to measuring quality of care in obstetrics.Am J Obstet Gynecol. 2016; 215: B8-B16
- SMFM scorecard 2020–2021.(Available at:)https://www.smfm.org/scorecard/2020Date: 2021Date accessed: September 28, 2021
- Provision of care, treatment, and services standards for maternal safety.(Available at:)https://www.jointcommission.org/-/media/tjc/documents/standards/r3-reports/r3_24_maternal_safety_hap_9_6_19_final1.pdfDate: 2019Date accessed: September 28, 2021
- Measure evaluation criteria. 2012.(Available at:)https://www.qualityforum.org/Measuring_Performance/Submitting_Standards/Measure_Evaluation_Criteria.aspx#usabilityDate accessed: September 28, 2021
Publication stageIn Press Journal Pre-Proof
The Alliance for Innovation on Maternal Health (AIM) is a cooperative agreement between the American College of Obstetricians and Gynecologists (ACOG) and the Maternal Child Health Bureau of the United States Health Resources and Services Administration. AIM seeks to provide standardized approaches to address the drivers of maternal mortality and severe maternal morbidity in the United States. E.M. is a Consulting Quality Improvement Director for AIM. I.T. and C.A. are ACOG staff for the AIM program.
All authors and Committee members have filed a disclosure of interests delineating personal, professional, business, or other relevant financial or nonfinancial interests in relation to this publication. Any substantial conflicts of interest have been addressed through a process approved by the Society for Maternal-Fetal Medicine (SMFM) Board of Directors. SMFM has neither solicited nor accepted any commercial involvement in the specific content development of this publication.
This document has undergone an internal peer review through a multilevel committee process within SMFM. This review involves critique and feedback from the SMFM Patient Safety and Quality and Document Review Committees and final approval by the SMFM Executive Committee. SMFM accepts sole responsibility for document content. SMFM publications do not undergo editorial and peer review by the American Journal of Obstetrics & Gynecology. The SMFM Patient Safety and Quality Committee reviews publications every 36 to 48 months and issues updates as needed. Further details regarding SMFM Publications can be found at www.smfm.org/publications.
SMFM recognizes that obstetrical patients have diverse gender identities and is striving to use gender-inclusive language in all of its publications. SMFM will be using terms such as “pregnant person/persons” or “pregnant individual/individuals” instead of “pregnant woman/women” and will use the singular pronoun “they.” When describing the study populations used in research, SMFM will use the gender terminology reported by the study investigators.
Reprints will not be available.